



**April 12, 2018**

John C. Rademacher, Chief Executive Officer  
Option Care, Inc.  
3000 Lakeside Drive, Suite 300N  
Bannockburn, Illinois 60015

Dear Mr. Rademacher:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Option Care, Inc., located at 14220 Northbrook Drive, Suite 100B, San Antonio, Texas, from July 17, 2017, to July 21, 2017, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Texas State Board of Pharmacy for follow up.


When the Agency considers an inspection to be “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment and we have enclosed a copy with this letter.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If you have any questions about the released information, please contact Thao Ta, Compliance Officer, at 214-253-5217 or via e-mail at [Thao.Ta@fda.hhs.gov](mailto:Thao.Ta@fda.hhs.gov) and/or me at 214-253-5288.

Sincerely,

John W.  
Diehl -S

 Digitally signed by John W. Diehl -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=John W. Diehl -  
S,  
0.9.2342.19200300.100.1.1=2000099727  
Date: 2018.04.12 15:27:41 -05'00'

LCDR John W. Diehl, M.S.  
Director, Compliance Branch  
Office of Pharmaceutical Quality Operations,  
Division II

U.S. Food & Drug Administration  
Office of Pharmaceutical Quality Operations, Division 2  
4040 North Central Expressway, Suite 300  
Dallas, TX 75204-3158  
[www.fda.gov](http://www.fda.gov)